Potential renoprotective effects of the angiotensin receptor blocker eprosartan: A review of preliminary renal studies

Cardiovascular Journal of South Africa

Volumn 15, Issue 1, 2004, Pages 32-37

  Rayner, Brian ^a   Jaeger, Bodo ^b   Verboom, Cees Nico ^b   Pascoe, Michael ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; RAMIPRIL; THIAZIDE DIURETIC AGENT; VALSARTAN;

AREA UNDER THE CURVE; BLOOD PRESSURE REGULATION; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRUG TOLERANCE; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY INJURY; PATHOGENESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SYSTEMIC CIRCULATION;

ACRYLATES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; IMIDAZOLES; KIDNEY; KIDNEY DISEASES; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; SEVERITY OF ILLNESS INDEX; THIOPHENES;

EID: 1842429668     PISSN: 10159657     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Oparil S, Haber E. The renin-angiotensin system (first of two parts). New Engl J Med 1974; 291: 389-401.
2. Hall JE. Control of sodium excretion by angiotensin II: intrarenal mechanisms and blood pressure regulation. Am J Physiol 1986; 250: R960-R972.
3. Ram CV, Vergne-Marini P. Role of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in the prevention of progression of renal disease. Curr Hypertens Rep 1999; 1: 431-435.
4. Fliser D, Haller H. Angiotensin II subtype 1-receptor antagonists in the treatment of diabetic nephropathy. J Hypertens 2001; 19(Suppl 1): S57-S60.
5. Ichikawi I, Harris RC. Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int 1991; 40: 583-596.
6. Bilous RW. Risk factors for the progression of renal disease in type 2 diabetes. In: Ritz E, Rychlik I, eds. Nephropathy in Type 2 Diabetes. Oxford: Oxford University Press, 1999: 89-110.
7. Frei U, Schindler R, Koch KM. Influence of antihypertensive therapy on renal function. Clin Investig 1992; 70(Suppl 1): S120-S126.
8. Balt JC, Mathy MJ, Pfaffendorf M, van Zwieten PA. Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan. J Hypertens 2001; 19: 2241-2250.
9. Esler M. The sympathetic system and hypertension. Am J Hypertens 2000; 13: 99S-105S.
10. Gavras I, Gavras H. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin 1999; 15: 15-24.
11. Levine B. Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin 1999; 15: 25-32.
12. Levine B. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension. Curr Med Res Opin 2001; 17: 8-17.
13. Elliott WJ. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. J Hum Hypertens 1999; 13: 413-417.
14. Gradman AH, Gray J, Maggicomo F, Punzi H, White WB. Assessment of once-daily eprosartan, an angiotensin II antagonist in patients with systemic hypertension. Clin Ther 1999; 21: 442-453.
15. Weber M. Clinical efficacy of eprosartan. Pharmacotherapy 1999; 19: 95S-101S.
16. Ruilope L, Jäger B, Prichard B. Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Bl Pressure 2001; 10: 223-229.
17. Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med 2001; 161: 2661-2667.
18. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
19. Sachse A, Verboom CN, Jäger B. Efficacy and safety of eprosartan in combination with HCTZ in patients with essential hypertension. J Hum Hypertens 2002; 16: 169-176.
20. Tenero DM, Martin DE, Miller AK, Ilson B, Boike SC, Zariffa N, et al. Effect of age and gender on the pharmacokinetics of eprosartan. Br J Clin Pharmacol 1998; 46: 267-270.
21. Martin DE, Chapelsky MC, Ilson B, Tenero D, Boike SC, Zariffa N, et al. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment. J Clin Pharmacol 1998; 38: 129-137.
22. Blum RA, Kazierad DJ, Tenero DM. A review of eprosartan pharmacokinetics and pharmacodynamic interaction studies. Pharmacotherapy 1999; 19: 79S-85S.
23. Sica DA. Kinetics of angiotensin-converting enzyme inhibitors in renal failure. J Cardiovasc Pharmacol 1992; 20(Suppl 10): S13-S20.
24. Price DA, De'Oliveira JM, Fisher ND, Hollenberg NK. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension 1997; 30(2 Pt 1): 240-246.
25. Hollenberg NK. Pharmacologic interruption of the renin-angiotensin system and the kidney: differential responses to angiotensin-converting enzyme and renin inhibition. J Am Soc Nephrol 1999; 10(Suppl 11): S239-S242.
26. 1-receptor antagonist, in sodium-replete healthy men. Clin Pharmacol Ther 1998; 63: 471-481.
27. Hollenberg NK, Osei SY, Lansang MC, Price DA, Fisher ND. Salt intake and non-ACE pathways for intrarenal: angiotensin II generation in man. J Renin Angiotensin Aldosterone Sys 2001; 2: 14-18.
28. Miller JA, Floras JS, Zinman B, Skorecki KL, Logan AG. Effect of hyperglycaemia on arterial pressure, plasma renin activity and renal function in early diabetes. Clin Sci (Lond) 1996; 90: 189-195.
29. Osei SY, Price DA, Fisher ND, Porter L, Laffel LM, Hollenberg NK. Hyperglycemia and angiotensin-mediated control of the renal circulation in healthy humans. Hypertension 1999; 33(1 Pt 2): 559-564.
30. Osei SY, Price DA, Laffel LM, Lansang MC, Hollenberg NK, et al. Effect on angiotensin II antagonist eprosartan on hyperglycaemia-induced activation of intrarenal renin-angiotensin system in healthy humans. Hypertension 2000; 36(1): 122-126.
31. Sica DA, Hollenberg NK. The renal profile of eprosartan. Pharmacotherapy 1999; 19(4 Pt 2): 86S-94S.
32. Parving HH. Hypertension and diabetes: the scope of the problem. Blood Press Suppl 2001; (Suppl 2): 25-31.
33. Muirhead N. The rationale for early management of chronic renal insufficiency. Nephrol Dial Transplant 2001; 16(Suppl 7): 51-56.
34. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. for the African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719-2728.
35. Sica DA, Douglas JG. The African American Study of Kidney Disease and Hypertension (AASK): new findings. J Clin Hypertens (Greenwich) 2001; 3: 244-251.
36. Plum J, Bunten B, Nemeth R, Grabensee B. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 1998; 9: 2223-2234.
37. Muirhead N, Feagan BF, Mahon J, et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Curr Ther Res 1999; 60: 650-660.
38. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Amer P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New Engl J Med 2001; 345: 870-878.
39. Wheeldon NM, Viberti G, for the MARVAL Trial. Microalbuminuria reduction with valsartan (abstract). Am J Hypertens 2001; 14(4 Suppl 1): A2.
40. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al., Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New Engl J Med 2001; 345(12): 851-860.
41. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med 2001; 345: 861-869.